Click here for slides on this topic


Cholesterol

A waxy lipid. Cholesterol circulates in the blood as part of a lipoprotein complex. High cholesterol levels put one at increased risk for atherosclerosis. (See high-density lipoprotein cholesterol, low-density lipoprotein cholesterol.)


The following content matched the glossary term: Cholesterol

AHA ADA prevention of CVD in T2D - Cholesterol Management

Top

Summary of cholesterol management recommendations from the AHA ADA cardiovascular disease (CVD) prevention in type 2 diabetes guidelines.

ADA 2016 Cardiovascular Disease (CVD) and Diabetes

Top

Recommendations for CVD management, including lipids and BP, in patients with type 2 diabetes from the 2016 ADA diabetes guidelines

ADA 2016 Glycemic Targets

Top

Glycemic targets and A1C for adults with diabetes from the 2016 ADA guidelines

Clinical Insights in Diabetes Newsletter October 2013

Top

Clinical Insights® in Diabetes newsletter October 2013

Exploring DPP-4 CV safety in SAVOR-TIMI 53 and EXAMINE, CV outcomes in Look AHEAD, relationship between gastric bypass and A1C and cardiometabolic risk factors, metabolic effects of bariatric surgery and medical therapy in STAMPEDE, statin use and diabetes risk, severe hypoglycemia and CVD disease risk.

Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia

Top

Ikramuddin S, Korner J, Lee W-J, et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia. JAMA. 2013;309(21):2240-2249.

Do statins interfere with lifestyle intervention in the prevention of diabetes in primary healthcare? One-year follow-up of the FIN-D2D project

Top

Rautio N, Jokelainen J, Oksa H, et al. Do statins interfere with lifestyle intervention in the prevention of diabetes in primary healthcare? One-year follow-up of the FIN-D2D project. BMJ Open. 2012;2(5). pii: e001472. doi: 10.1136/bmjopen-2012-001472. Treatment with statins has been linked to an increased risk for type 2 diabetes in several post-hoc evaluations of previous completed trials, leading to controversy regarding the risk/benefit profile of statin therapy for primary prevention in patients who are at low risk for developing cardiovascular (CV) events.

NDEI.org Press Release Expert Commentary on Halted Look AHEAD Trial from Anne Peters, MD

Top

Anne Peters, MD, on the Halted Look AHEAD Trial: "Prevention of Obesity and Diabetes Remains Key" NDEI.org expert commentary offers insights on discontinuation of lifestyle intervention trial October 26, 2012: NDEI.org, the official website of The National Diabetes Education Initiative® (NDEI®), published today expert commentary from Anne Peters, MD, on the discontinuation, 2 years premature, of the Look AHEAD (Action for Health in Diabetes) trial, in which lifestyle intervention failed to reduce cardiovascular outcomes among people with type 2 diabetes.

NDEI.org Press Release Peter Libby, MD, on New JUPITER Analysis: “These Data Put Diabetes Risk from Statin Therapy in Perspective”

Top

Peter Libby, MD, on New JUPITER Analysis: "These Data Put Diabetes Risk from Statin Therapy in Perspective" NDEI.org expert commentary explores statins and diabetes risk September 18, 2012: NDEI.org, the official website of The National Diabetes Education Initiative® (NDEI®) published expert commentary from Peter Libby, MD, on a new analysis of the landmark JUPITER primary prevention trial demonstrating that the cardiovascular and mortality benefits conferred by statin therapy outweigh the risk for developing diabetes among patients at low risk for cardiovascular disease (CVD).

Association of weight status with mortality in adults with incident diabetes

Top

Carnethon MR, De Chavez PJ, Biggs ML, et al. Association of weight status with mortality in adults with incident diabetes. JAMA. 2012;308(6):581-590. Carnethon and colleagues analyzed data from five clinical trials to compare mortality rates among subjects who were normal weight with subjects who were overweight/obese at the time of incident adult-onset diabetes.

1 2 3 4 5 6 7 8 9 10  ... Next 

Slide Library Results

Search Results for: Cholesterol Slides Found: 176
Prevalence of the Insulin Resistance Syndrome (NCEP) in the US Population
Relationship Between Flow-Mediated Brachial Artery Dilation and Weight Loss After Lifestyle Modification
Effect of Phentermine on Weight Loss in Obese Patients With Type 1 or Type 2 Diabetes
Effect of Sibutramine on Weight Loss in Obese Patients With Type 2 Diabetes Treated With Metformin
Effect of Continuous and Intermittent Sibutramine on Lipids
Effect of Orlistat on Lipids and Glycemic Control in Patients
ACP Guidelines on Management of Dyslipidemia in Type 2 Diabetes
Effect of Early Thiazolidinedione Therapy on A1C Levels
Effect of Early Thiazolidinedione Therapy on C-Peptide Levels
Effect of Early Thiazolidinedione Therapy on Diabetes Onset
Gender Differences Influence Impact of Type 2 Diabetes on CHD Risk
ARIC: Association Between MetS Components and CHD Risk
Effect of 4 Diets on Weight Loss and Cardiac Risk Factors
PPARa and HDL Metabolism (animated)
PPARg Exerts Antiatherogenic Effects via Multiple Vascular Targets (animated)
Results From Statin Trials for Patients With Diabetes
Non–HDL-C as a Predictor of Risk for CHD in Diabetes
Vildagliptin Is as Effective as Rosiglitazone in Lowering A1C but Without Weight Gain in Drug-Naïve Patients With T2D
SPARCL: Primary Outcome of Fatal or Nonfatal Stroke
SPARCL: First Events
TNT: Intensive Atorvastatin Treatment Reduces Cardiovascular Events in Patients With CHD and Diabetes
Inadequate Achievement of ADA Goals Among US Adults With Diabetes
Drug Nonadherence Is Associated With Adverse Clinical Outcomes in Diabetes
ADOPT: Adverse Events
Vildagliptin vs Rosiglitazone Monotherapy in Type 2 Diabetes: Effects on Lipids
GLAI: Comparison of TZDs on Lipoprotein Subclass Particle Size
Proportion of Diabetic Patients With Low HDL-C Stratified by Treatment, Sex, and Cardiovascular Disease
Steno-2: Percentage of Patients at Treatment Goals at End of Study
Retinopathy Stage, Mean A1C, and Mean Systolic Blood Pressure by Ethnicity
BLOOM-DM: Secondary Endpoints
JUPITER: Statin Therapy for Primary Prevention of Cardiovascular Disease—Rationale
JUPITER: Statin Therapy for Primary Prevention of Cardiovascular Disease—Participant Profile
AusDiab Substudy: Results
AusDiab Substudy: Physical Health Component Summary (PCS) Results
AusDiab Substudy: Mental Health Component Summary (MCS) Results
Roux-en-Y Gastric Bypass Surgery in Type 2 Diabetes and Mild Obesity: Additional Parameters
Pooled Analysis: Mortality Among Normal and Overweight/Obese Subjects with Diabetes
ADVANCE Post-hoc Analysis: Low HDL-C and Microvascular Event Risk
ADVANCE Post-hoc Analysis: HDL-C Predicts Microvascular Risk
VADT Post-hoc Analysis: Satin Use and CAC Progression
AIM-HIGH: Niacin + Statin Therapy for Cardiovascular Risk Reduction
AIM-HIGH: Design
AIM-HIGH: Baseline Characteristics
AIM-HIGH: Lipid Values at Baseline and 2 Years
AIM-HIGH: Rate of the Primary Endpoint
AIM-HIGH: Rate of Secondary Endpoints
CANTATA-D2: Design
CANTATA-D2: Effect of Canagliflozin Vs Sitagliptin on Lipid Values at 52 Weeks
CANTATA-M: Effect of Canagliflozin Vs Placebo on Lipid Values at 26 Weeks
CANTATA-M: Design
BP Rates and All-Cause Mortality in Newly Diagnosed Type 2 Diabetes: Results
Meta-Analysis: Risk for New-Onset Diabetes and CV Events with Intensive- Vs Moderate Dose Statins
Meta-Analysis: New-Onset Diabetes and CV Events With Intensive- Vs Moderate-Dose Statins
Meta-Analysis: New-Onset Diabetes With Intensive- Vs Moderate-Dose Statins
Meta-Analysis: CV Events With Intensive- Vs Moderate-Dose Statins
ACCORD: Factors Associated with Increased Hypoglycemia Risk in Intensive and Standard Treatment Arms
ADA Nutrition Guidelines: Fats
Long-Term Obesity Medications: At Least 5% Weight Loss After 1 Year
ACC/AHA Cholesterol Guidelines 2013: ASCVD Risk Reduction Is Goal
ACC/AHA Cholesterol Guidelines 2013: Statin Benefit Groups for ASCVD Prevention
ACC/AHA Cholesterol Guidelines 2013: ASCVD Statin Benefit Group 1: Secondary Prevention
ACC/AHA Cholesterol Guidelines 2013: ASCVD Statin Benefit Group 1: Primary Prevention LDL-C 190 or Higher
ACC/AHA Cholesterol Guidelines 2013: ASCVD Statin Benefit Group 3: Primary Prevention Diabetes
ACC/AHA Cholesterol Guidelines 2013: ASCVD Statin Benefit Group 4: Primary Prevention With 10-Yr ASCVD Risk 7.5% or Higher (No Diabetes)
ACC/AHA Cholesterol Guidelines 2013: High- and Moderate-Intensity Statin Therapy
ACC/AHA Cholesterol Guidelines 2013: The Argument Against LDL-C, Non-HDL-C Targets
ACC/AHA Cholesterol Guidelines 2013: Role of Biomarkers & Imaging Tests
ACC/AHA Cholesterol Guidelines 2013: LDL-C, Non-HDL-C Targets
ACC/AHA Cholesterol Guidelines 2013: Statin Therapy for Secondary Prevention
ACC/AHA Cholesterol Guidelines 2013: Statin Therapy for Primary Prevention: LDL-C 190 or Higher
ACC/AHA Cholesterol Guidelines 2013: Statin Therapy for Primary Prevention: Diabetes & LDL-C 70-189
ACC/AHA Cholesterol Guidelines 2013: Statin Therapy for Primary Prevention: LDL-C 70-189, No Diabetes
ACC/AHA Cholesterol Guidelines 2013: Heart Failure and Hemodialysis
ACC/AHA Cholesterol Guidelines 2013: High-Intensity Statin for Secondary ASCVD Prevention
ACC/AHA Cholesterol Guidelines 2013: Secondary ASCVD Prevention for Age >75 Years
ACC/AHA Cholesterol Guidelines 2013: Statin Initiation for Secondary Prevention: Age 75 Years or Younger
ACC/AHA Cholesterol Guidelines 2013: Statin Initiation for Secondary Prevention: Age 75 and Older
ACC/AHA Cholesterol Guidelines: Primary ASCVD Prevention for LDL-C 190 or Higher
ACC/AHA Cholesterol Guidelines 2013: Statin Initiation for Primary ASCVD Prevention: Age 40-75 With Diabetes or LDL 190 or Higher
ACC/AHA Cholesterol Guidelines 2013: Statin Initiation for Primary ASCVD Prevention: Age 40-75, LDL 70-189, No Diabetes
ACC/AHA Cholesterol Guidelines 2013: Primary ASCVD Prevention in Individuals With Diabetes
ACC/AHA Cholesterol Guidelines 2013: Primary ASCVD Prevention in Individuals With 70-189, No Diabetes
ACC/AHA Cholesterol Guidelines 2013: Primary ASCVD Prevention for Individuals Not in A Statin Benefit Group
ACC/AHA Cholesterol Guidelines 2013: 10-Yr ASCVD Risk Assessment Calculator: Primary Prevention
ACC/AHA Cholesterol Guidelines 2013: Statin Safety Recommendations: Maximizing Statin Safety
ACC/AHA Cholesterol Guidelines 2013: Statin Safety Recommendations: CK & ALT
ACC/AHA Cholesterol Guidelines 2013: Statin Safety Recommendations: Statin Dosing
ACC/AHA Cholesterol Guidelines 2013: Statin Safety Recommendations: Muscle Symptoms
ACC/AHA Cholesterol Guideline 2013: Statin Safety Recommendations: Cognitive Impairment
ACC/AHA Cholesterol Guidelines 2013: Nonstatin Safety Recommendations: Niacin
ACC/AHA Cholesterol Guidelines 2013: Nonstatin Safety Recommendations: Bile-Acid Sequestrants & Ezetimibe
ACC/AHA Cholesterol Guidelines 2013: Nonstatin Safety Recommendations: Fibrates
ACC/AHA Cholesterol Guidelines 2013: Nonstatin Safety Recommendations: Omega-3 Fatty Acids
ACC/AHA Cholesterol Guidelines 2013: Guidance on Nonstatin Therapies
ACC/AHA Cholesterol Guidelines 2013: Monitoring & Optimizing Statin Therapy
ACC/AHA Cholesterol Guidelines 2013: Insufficient Response to Statin Therapy
A1C CVD Outcomes in Adults Without Diabetes | Diabetes Slides | NDEI
A1C No Benefit CVD Risk Predication in Adults Without Diabetes | NDEI
ACC/AHA Lifestyle Management Guidelines LDL-C | NDEI
ACC AHA Lifestyle Guidelines Trans Fat Cholesterol | NDEI
ACC/AHA Cholesterol Guidelines 2013: Estimated 10-Yr ASCVD Risk Guides Statin Therapy
Canola Oil Diet Study Glycemia A1C Type 2 Diabetes | NDEI
Statin Potency New-Onset Diabetes Risk | NDEI
Statin Potency & Type 2 Diabetes Risk | NDEI
Diabetes Macrovascular Complications US Adults 2012 | NDEI
High-Potency Statins & Increased Diabetes Risk Secondary Prevention | NDEI
SGLT2 Inhibitors Type 2 Diabetes Treatment Slides | NDEI
Trends in CVD Risk ARIC Study | NDEI
Edinburgh Type 2 Diabetes Study Severe Hypoglycemia Slide PPT | NDEI
Edinburgh Type 2 Diabetes Hypoglycemia Macrovascular Slides PPT | NDEI
Edinburgh Type 2 Diabetes Hypoglycemia Linked to Inflammation Slides PPT | NDEI
Edinburgh Type 2 Diabetes Inflammation Doesn't Influence Hypoglycemia Slides PPT | NDEI
VA BEACH DIET Study: Impact of Diet on CVD Risk | NDEI
EMPA-REG Safety of Empagliflozin in Type 2 Diabetes & Hypertension SGLT2 | NDEI
CVD Treatment Statin ADA Type 1 Diabetes Guidelines | NDEI
AACE 2015 Diabetes Guidelines Dyslipidemia Treatment PPT | NDEI
Cholesterol Targets LDL Type 2 Diabetes AHA ADA Guidelines | NDEI
HOPE-3 Primary Prevention for Individuals at Intermediate CV Risk
HOPE-3 Statin Therapy for Intermediate CV Risk Reduction PPT | NDEI
HOPE-3 CV Event Reduction With Rosuvastatin Vs Placebo PPT | NDEI
HOPE-3 LDL & Lipoprotein Reductions With Rosuvastatin Vs Placebo | NDEI
HOPE-3 Safety of Rosuvastatin Vs Placebo PPT | NDEI
HOPE-3 Incidence Diabetes With Rosuvatatin Vs Placebo PPT | NDEI
HOPE-3 CV Event Reduction With Antihypertensive Therapy PPT | NDEI
HOPE-3 BP Reductions With Candesartan/HCTZ Vs Placebo PPT | NDEI
HOPE-3 Safety of Candesartan/HCTZ Vs Placebo BP PPT | NDEI
HOPE-3 Cholesterol- and BP-Lowering for Intermediate CV Risk Reduction | NDEI
HOPE-3 Lipid- & BP-Lowering Therapy for Primary Prevention PPT | NDEI
HOPE-3 Lipid- & BP-Lowering Intermediate Risk CV Events PPT | NDEI
Lifestyle Recommendations from the NLA Cholesterol Guidelines | CCMD
Diets for Cholesterol Lowering NLA Cholesterol Guidelines | CCMD
Nutrition Recommendations NLA Cholesterol Guidelines | CCMD
Nutrition Recommendations to Treat High TG NLA Cholesterol Guidelines | CCMD
Lipid Screening in Children & Adolescents NLA Cholesterol Guidelines | CCMD
Lipoprotein Screening in Children & Adolescents NLA Cholesterol Guidelines | CCMD
Cascade Screening ifor FH in Children & Adolescents NLA Cholesterol Guidelines
Lifestyle Interventions for Children & Adolescents NLA Cholesterol Guidelines
Lipid Pharmacotherapy for Children & Adolescents NLA Cholesterol Guidelines
Treating Dyslipidemia in Women NLA Cholesterol Guidelines | CCMD
Pharmacologic Therapy for Dyslipidemia in Women NLA Cholesterol Guidelines
Managing Dyslipidemia During Pregnancy NLA Cholesterol Guidelines | CCMD
Managing Dyslipidemia in Women With PCOS NLA Cholesterol Guidelines
Managing Dyslipidemia in Women During Menopause NLA Cholesterol Guidelines
Primary & Secondary ASCVD Prevention in Older Adults NLA Cholesterol Guidelines
ASCVD Risk Assessment in Older Adults NLA Cholesterol Guidelines | CCMD
Pharmacotherapy for Dyslipidemia in Older Adults NLA Cholesterol Guidelines
Managing Dyslipidemia in Hispanics/Latinos NLA Cholesterol Guidelines | CCMD
Managing Dyslipidemia in African-Americans NLA Cholesterol Guidelines
Managing Dyslipidemia in Individuals With HIV NLA Cholesterol Guidelines
Managing Residual Risk After Lifestyle & Statin Therapy NLA Cholesterol Guidelines
PCSK9 Inhibitors for Residual CV Risk NLA Cholesterol Guidelines | CCMD
NLA Dyslipidemia Guidelines Summary CVD Slides | CCMD
NLA Cholesterol Guidelines LDL-C Treatment Targets | CCMD
NLA Cholesterol Guidelines Lipid Screening Recommendations PPT | CCMD
NLA Cholesterol Guidelines Lipid Treatment Goals | CCMD
NLA Guidelines Cholesterol & Triglyceride Targets CVD Slides | CCMD
NLA Guidelines Cholesterol Targets for Therapy CVD Slides | CCMD
NLA Guidelines Atherogenic Cholesterol Levels for Primary Prevention | CCMD
NLA Cholesterol Guidelines Lipid Treatment Goals | CCMD
NLA Guidelines CVD Risk Categories & Lipid Treatment | CCMD
NLA Cholesterol Guidelines Metabolic Syndrome Criteria | CCMD
NLA Cholesterol Guidelines ASCVD Risk Factors Slides | CCMD PPT
NLA Cholesterol Guidelines High or Very-High ASCVD Risk | CCMD
Very-High ASCVD Risk LDL Goals NLA Cholesterol Guidelines | CCMD
LDL-C Target for High ASCVD Risk NLA Cholesterol Guidelines | CCMD
NLA Cholesterol Guidelines Moderate ASCVD Risk PPT | CCMD
NLA Cholesterol Guidelines Low ASCVD Risk PPT | CCMD
ASCVD Risk Assessment Algorithm NLA Cholesterol Guidelines | CCMD
NLA Cholesterol Guidelines ASCVD Risk Refinement PPT | CCMD
NLA Cholesterol Guidelines Lifestyle Therapy ASCVD Risk PPT | CCMD
Cholesterol Treatment Algorithm to Reduce ASCVD NLA Guidelines | CCMD
Hypertriglyceridemia Management NLA Cholesterol Guidelines PPT | CCMD
Combination Lipid-Lowering Therapy NLA Cholesterol Guidelines PPT | CCMD
Severe Hypercholesterolemia Management FH NLA Cholesterol Guidelines | CCMD
FH Treatment & Management PCSK9 NLA Cholesterol Guidelines | CCMD
FH Treatment LDL-Apheresis NLA Cholesterol Guidelines PPT | CCMD